+1 858-523-8231
Login | Register
AA Blocks, Building Blocks, Catalysts, Inhibitors
Login | Register
Home Other Building Blocks 1239908-20-3
1239908-20-3,MFCD29767859
Catalog No.:AA000L8Y

1239908-20-3 | Ixazomib citrate

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
98%
in stock  
$7.00   $5.00
- +
2mg
98%
in stock  
$9.00   $7.00
- +
100mg
98%
in stock  
$96.00   $68.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA000L8Y
Chemical Name:
Ixazomib citrate
CAS Number:
1239908-20-3
Molecular Formula:
C20H23BCl2N2O9
Molecular Weight:
517.1216
MDL Number:
MFCD29767859
SMILES:
CC(C[C@@H](B1OC(=O)C(O1)(CC(=O)O)CC(=O)O)NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)C
Properties
Computed Properties
 
Complexity:
797  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
1  
Heavy Atom Count:
34  
Hydrogen Bond Acceptor Count:
9  
Hydrogen Bond Donor Count:
4  
Rotatable Bond Count:
11  

Downstream Synthesis Route
CASUnavailable 
  77-92-9    1239908-20-3 

[1]CurrentPatentAssignee:ADVENTINTERNATIONALCORPORATION-WO2016/155684,2016,A1Locationinpatent:Page/Pagecolumn4;9;10

[2]CurrentPatentAssignee:CHENGDUBEISIKAIRUIBIOTECHNOLOGY-CN106986884,2017,ALocationinpatent:Paragraph0052;0054

[3]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2017/222819,2017,A2Locationinpatent:Paragraph00141;00146;00147;00148;00149

[4]CurrentPatentAssignee:MSNLABORATORIESPRIVATELIMITED-WO2018/173071,2018,A1Locationinpatent:Page/Pagecolumn17

[1]CurrentPatentAssignee:CHENGDUBEISIKAIRUIBIOTECHNOLOGY-CN106986884,2017,ALocationinpatent:Paragraph0037;0047-0050

[2]CurrentPatentAssignee:PEKINGUNIVERSITY-CN108794520,2018,ALocationinpatent:Paragraph0015;0069-0088

[3]CurrentPatentAssignee:ADVENTINTERNATIONALCORPORATION-WO2016/155684,2016,A1Locationinpatent:Page/Pagecolumn2;4;11

[1]CurrentPatentAssignee:ADVENTINTERNATIONALCORPORATION-WO2016/155684,2016,A1

[2]CurrentPatentAssignee:ADVENTINTERNATIONALCORPORATION-WO2016/155684,2016,A1

[3]CurrentPatentAssignee:MSNLABORATORIESPRIVATELIMITED-WO2018/173071,2018,A1

667403-46-5   
2,2’-{2-(1R)-1-((2,5-dichlorobenzoyl)aminoacetyl}amino)-3-methylbutyl-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diaceticacid 

[1]Patent:WO2016/155684,2016,A1

[2]Patent:CN106608883,2017,A

[3]Patent:CN106478701,2017,A

[4]Patent:CN106478701,2017,A

[5]Patent:CN106478701,2017,A

[6]Patent:CN106478701,2017,A

[7]Patent:CN106478701,2017,A

[8]Patent:CN106478701,2017,A

[9]Patent:CN106478701,2017,A

[10]Patent:CN106478701,2017,A

[11]Patent:WO2018/158697,2018,A1

[12]Patent:US10118937,2018,B1

[1]CurrentPatentAssignee:VIATRISINC-WO2017/46815,2017,A1Locationinpatent:Page/Pagecolumn20;21

Literature

Title: Liu R, et al. A New Perspective for Osteosarcoma Therapy: Proteasome Inhibition by MLN9708/2238 Successfully Induces Apoptosis and Cell Cycle Arrest and Attenuates the Invasion Ability of Osteosarcoma Cells in Vitro. Cell Physiol Biochem. 2017 Jan 27;41(2

Title: Chauhan D, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011 Aug 15;17(16):5311-21.

Title: Kupperman E, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010 Mar 1;70(5):1970-80.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 1239908-20-3
1201902-80-8

1201902-80-8

 133876-92-3

133876-92-3
Building Blocks
More >
Tags:1239908-20-3 Molecular Formula|1239908-20-3 MDL|1239908-20-3 SMILES|1239908-20-3 Ixazomib citrate